Anticoagulation and thrombolytic therapy. Practical considerations.
Although thrombolytic agents have been available for over 10 years and have demonstrated safety and efficacy in an increasing number of clinical conditions involving thrombotic phenomena, their general acceptance as first-line therapeutic agents in medical management has been slow. Much of the reluctance to use these drugs is based on their associated incidence of hemorrhagic complications, which is several-fold greater than with use of conventional anticoagulants. With the introduction of second-generation thrombolytic agents, made possible through successes in recombinant DNA technology and chemical modifications of previously available compounds, increased fibrin specificity has been achieved and has been translated into increased clinical efficacy and safety. These results will likely improve as innovative regimens using dose modifications or multiple agents with combined synergy are developed. An appreciation of basic coagulation and the pharmacology of anticoagulants and thrombolytic agents is necessary to maximize the benefits of currently available medications, to develop new treatment strategies, and to minimize potential hemorrhagic complications.
Kessler
C M
CM
Division of Hematology-Oncology, George Washington University Medical Center, Washington, D.C.
D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010973:Platelet Adhesiveness; D010974:Platelet Aggregation; D013927:Thrombosis / Q000188:drug therapy*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D006493:Heparin